Shares of AngioDynamics Inc. (NASDAQ:ANGO) were up 1% on Tuesday . The company traded as high as $16.81 and last traded at $16.72, with a volume of 213,954 shares. The stock had previously closed at $16.55.

A number of analysts recently weighed in on ANGO shares. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a report on Wednesday, June 8th. Canaccord Genuity lowered shares of AngioDynamics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $14.50 to $13.00 in a report on Tuesday, April 5th. Piper Jaffray Cos. started coverage on shares of AngioDynamics in a report on Friday, April 8th. They set a “neutral” rating and a $12.00 target price on the stock. Finally, KeyCorp decreased their target price on shares of AngioDynamics from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, April 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. AngioDynamics presently has a consensus rating of “Hold” and a consensus price target of $14.10.

The company has a 50-day moving average price of $13.95 and a 200-day moving average price of $12.08. The company’s market capitalization is $605.97 million.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, July 13th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.03. The company had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $88.64 million. The business’s revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.14 EPS. Equities analysts expect that AngioDynamics Inc. will post $0.63 earnings per share for the current year.

In related news, SVP Stephen A. Trowbridge sold 12,940 shares of the firm’s stock in a transaction that occurred on Monday, April 25th. The shares were sold at an average price of $12.30, for a total value of $159,162.00. Following the transaction, the senior vice president now owns 32,469 shares of the company’s stock, valued at $399,368.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Charles R. Greiner sold 3,508 shares of the firm’s stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $12.31, for a total transaction of $43,183.48. Following the completion of the transaction, the vice president now directly owns 20,910 shares in the company, valued at approximately $257,402.10. The disclosure for this sale can be found here.

Other institutional investors have bought and sold shares of the company. Lapides Asset Management LLC increased its position in AngioDynamics by 1.2% in the fourth quarter. Lapides Asset Management LLC now owns 700,500 shares of the company’s stock worth $8,504,000 after buying an additional 8,400 shares during the last quarter. Whitebox Advisors LLC acquired a new position in AngioDynamics during the fourth quarter worth about $1,384,000. Royce & Associates LLC increased its position in AngioDynamics by 19.0% in the fourth quarter. Royce & Associates LLC now owns 640,801 shares of the company’s stock worth $7,779,000 after buying an additional 102,098 shares during the last quarter. Morgan Stanley increased its position in AngioDynamics by 6.2% in the fourth quarter. Morgan Stanley now owns 98,634 shares of the company’s stock worth $1,198,000 after buying an additional 5,728 shares during the last quarter. Finally, Nationwide Fund Advisors increased its position in AngioDynamics by 252.9% in the fourth quarter. Nationwide Fund Advisors now owns 88,374 shares of the company’s stock worth $1,073,000 after buying an additional 63,332 shares during the last quarter.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.